Nazca was founded in 2001, with the objective of becoming the leading manager of private equity funds to invest in small and medium-sized Spanish companies.

To this end, the company has clearly defined its investment criteria, which are as follows:

• Invest only in companies that are leaders in their markets, have a proven track record, minimum sales of €10m and attractive growth opportunities.
• An equity contribution in the range of €7 to €50 million, through significant majority or minority shareholdings, and always using prudent levels of debt financing.
• An average tenure of 3 to 6 years in the companies where he invests.

TYPES OF OPERATIONS

It is worth noting that most of the investments of Nazca are carried out in family businesses, either by acquiring them and professionalising their management team or by sharing a project.

The most common scenarios are:

• Equity buy-outs to support management teams, providing strategic, operational and financial insight.
• Capital increase in growth projects by acquiring majority or significant minority stakes.
• Capital for acquisitions

LATEST NAZCA ACQUISITIONS

CINELUX

Founded in 1988, with its headquarters in Madrid and two subsidiaries in Barcelona, it is the largest operator and market leader in the rental of lighting equipment for television, fiction, cinema and events..

Sales of Cinelux in 2018 was €12m, a double-digit upward trend derived from the growing trend towards outsourcing its services, as well as the company's ability to offer its customers the most innovative machinery, thanks to the fact that it has the largest fleet of lighting machinery in the Spanish market.

The aim of this operation is none other than to take advantage of the important opportunities presented by the audiovisual business in our country.

DIATER

Just one month earlier, Nazca also acquired an 85% stake in the biopharmaceutical company Diatera Madrid-based pharmacist specialising in allergy treatment with immunotherapy.

The transaction is valued at €45m, which will enable the pharma company to enhance its growth through the development and innovation of new diagnostic products and treatments, and to enter new segments, both domestically and internationally.

To this end, Diater plans to strengthen its production facilities and to source the main raw materials.

TERRATEST

However, Nazca's largest operation is the acquisition of the 100% from the company Terratesta firm specialised in special foundations, tunnels and ground improvement for large infrastructure and building projects. present in 25 countries.